Macrogenics Inc. (MGNX) Insider Trading

Last 12 months

Insiders sold $129k and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Aug 2025.

Net open-market

−$129k

0 buys · 1 sale

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 1

executives and directors

Last open-market buy

Aug 2025

Aug 20, 2025

Get an email when MGNX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 19	Jeffrey Stuart Peters Senior VP, GC, and Secretary	Sold10b5-1 plan	31,105	$4.15	$129k	100%	Form 4
Aug 19, 2025 – Aug 20, 2025	William K Heiden Director	Bought 2 parts	100,000	$1.51 average	$151k	909%	Form 4
Feb 15, 2025	Beth Ann Smith VP, Controller & Treasurer	SoldNo plan	423	$2.56	$1k	4.2%	Form 4

Aug 1910b5-1 plan
Jeffrey Stuart Peters
Senior VP, GC, and Secretary · sold 31,105 at $4.15
$129k
100% of stake
Aug 19, 2025 – Aug 20, 2025
William K Heiden
Director · bought 100,000 at avg $1.51
$151k
909% of stake
Feb 15, 2025No plan
Beth Ann Smith
VP, Controller & Treasurer · sold 423 at $2.56
$1k
4.2% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch MGNX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

LFVNLifeVantage Corporation

ABUSArbutus Biopharma Corporation

AMRNAmarin Corp PLC\Uk

CYRXCryoport Inc.

URGNUrogen Pharma Ltd.

SLNOSoleno Therapeutics Inc

NUVBNuvation Bio Inc.

DAWNDay One Biopharmaceuticals, Inc.

Spot a number that looks wrong? Check it in MGNX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing MGNX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.